# A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

> **NCT05987358** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 165 (estimated)

## Conditions studied

- Biliary Carcinoma

## Interventions

- **DRUG:** TQB3454 tablets
- **DRUG:** TQB3454 tablets matching placebo

## Key facts

- **NCT ID:** NCT05987358
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987358, "A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05987358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*